Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

No definition available.

+ Details

Name:	us-gaap_BusinessAcquisitionLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 25

-Paragraph 23

-URI http://asc.fasb.org/extlink&oid=34752592&loc=d3e1043-128460

+ Details

Name:	us-gaap_BusinessCombinationAcquisitionRelatedCosts
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 50

-Paragraph 4

-Subparagraph (a)(1)

-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7008-128479

+ Details

Name:	us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Details

Name:	us-gaap_BusinessAcquisitionAxis=shpgf_NpsPharmaceuticalsIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	shpgf_AcquisitionIntegrationCostsAxis=shpgf_AcquisitionIntegrationGrossMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_BusinessAcquisitionAxis=shpgf_ViropharmaIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_BusinessAcquisitionAxis=shpgf_SarcodeBiosciencesIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_BusinessAcquisitionAxis=shpgf_LumenaPharmaceuticalsIncAndLotusTissueRepairIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_BusinessAcquisitionAxis=shpgf_SarcodeBioscienceIncAndFerrokinBioscienceIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	shpgf_AcquisitionIntegrationCostsAxis=shpgf_AcquisitionIntegrationNetMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Integration and acquisition costs (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Business Acquisition [Line Items]
Integration and acquisition costs	$ (212.4)	$ 112.1	$ (136.7)	$ 118.7
NPS Pharma
Business Acquisition [Line Items]
Integration and acquisition costs	47.8		117.7
Acquisition and Integration Costs, Gross Amount \| NPS Pharma
Business Acquisition [Line Items]
Integration and acquisition costs	47.8		117.7
Acquisition and Integration Costs, Gross Amount \| Viropharma
Business Acquisition [Line Items]
Integration and acquisition costs		31.5		97.3
Acquisition and Integration Costs, Gross Amount \| SARcode
Business Acquisition [Line Items]
Change in fair value of contingent consideration		80.6
Acquisition and Integration Costs, Gross Amount \| Lumena and Lotus Tissue Repair
Business Acquisition [Line Items]
Change in fair value of contingent consideration	(258.1)		(255.7)
Acquisition and Integration Costs, Gross Amount \| SARcode and Ferrokin Bioscience, Inc
Business Acquisition [Line Items]
Change in fair value of contingent consideration				21.4
Acquisition and Integration Costs, Net Amount
Business Acquisition [Line Items]
Integration and acquisition costs	$ (212.4)	$ 112.1	$ (136.7)	$ 118.7